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Objectives. To evaluate the efficacy of silver- or Triclosan-coated prosthetic material compared to Rifampin bonded Dacron
concerning their resistance to infection following subcutaneous implantation and contamination with Staphylococcus
aureus.
Design. Animal experimental study in mice.
Material and methods. Thirty-six C3H/HcN mice (Charles River Lab., Sulzfeld, Germany) with a weight between 24 and
27 g were randomised into six groups counting six animals each. Group I: control, gel-sealed dacron graft, group II: gel-
sealed dacron graft and local contamination, group III: Intergardw-Silver-prosthesis and contamination, group IV:
silver/gel-sealed dacron prosthesis (test graft) and contamination, group V: Rifampin-bonded gel-sealed graft and
contamination, group VI: Triclosan/collagen-coated dacron graft and contamination. Dacron graft material 0.8 £ 1 cm was
subcutaneously implanted in mice. Local contamination with 2 £ 107/0.2 ml S. aureus ATCC 25923 was carried out in
groups II to VI. On day 14 the animals were killed and the grafts were explanted. The microscopic, histologic and
microbiological evaluation of the graft material and the perigraft tissue was performed.
Results. In control group I no case of infection was detected. In group II, 6 of 6 animals showed infection. In group III
(Intergardw-Silver) and group IV (silver/gel-test graft) were 6 of 6, in group V (Rifampin) only 1 of 6 grafts and in group VI
(Triclosan) 4 of 6 grafts were infected. The difference between the low rate of infection in group V (Rifampin) in comparison
to the completely infected groups III and IV (Silver) as well as the control group II was significant. Treatment of grafts with
Triclosan could prevent infection only in 1/3 of the cases in group IV.
Conclusion. Silver coating failed to prevent graft infection material. A potential antimicrobial property was evident for
Triclosan whereas Rifampin-bonded grafts exhibit a significantly reduced infection rate. Thus, silver-coated vascular grafts
cannot ensure protection from vascular graft infection.
Key Words: Vascular graft infection; Silver coating; Rifampin; Triclosan; Standardised infection model.
Introduction
The reported incidence of vascular graft infection is
between 0.5 and 5%.1 – 4 The mortality in the presence
of vascular graft infections varies between 25 and
75%,5,6 and the rate of limb loss in infrainguinal
vascular bypass infection may reach 79%.7,8 Following
the manifestation of a vascular graft infection the gold
standard in the treatment is the explantation of the
infected graft, extensive excision of perigraft tissue
followed by the reconstruction with an extraanatomic
bypass. In 1990 the reconstruction with in situ graft
replacement using antimicrobially protected grafts
was introduced. Recently, autologous and homolo-
gous graft reconstructions have been performed with
promising results. Although homologous and auto-
logous reconstructions lead to good outcome, there
availability is limited. In particular cases the use of
Dacron material cannot be avoided.
In surgical meetings successful case reports of
Dacron vascular grafts coated with the novel agent
Triclosan have been propagated for in situ reconstruc-
tion in vascular graft infections.9 Similarly, in a pig
vascular graft infection model positive effects of
Triclosan on the infection rate have been shown.10
Presently, silver coated grafts are utilized for in situ
reconstruction in case of vascular graft infection,
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despite the fact that there are no in vivo examinations
available proving the efficacy.
The aim of our study, therefore, was to test the
antimicrobial properties of dacron grafts treated with
silver-or Triclosan and compare those results with the
previously established Rifampin bounded prosthetic
material. To address this issue a standardised well
characterised experimental mouse model was used in
which infected graft material treated with various
agents was implanted.
Material and Methods
Thirty-six male C3H/HcN mice (Charles River Lab.,
Sulzfeld, Germany), 6–7 weeks old with a weight
between 24 and 27 g were used in the trial. (The
C3H/HeN mice were used in this study since they
have a balanced Th1–Th2 immune response and are
therefore similar to the immune system in humans.)
All animal care complied with the principals of
Laboratory Animal Care and the Guide for the Care
and Use of Laboratory Animals (Tierschutzgenehmi-
gung und Versuchsgenehmigung, Government Ober-
bayern/Germany).
Graft material. Commercially available standard
grafts (Silver Intergardw Intervascular, La Ciotat,
France and Uni-Graftw DV, B. Braun Melsungen AG,
Melsungen, Germany) as well as a not commercially
available silver/gelatine-coated dacron graft were
used in the study. All grafts had a diameter of 8 mm.
They were cut to a size of 0.8 £ 1 cm. The graft material
in the groups I, II, III, IV and V were autoclaved and
graft material in group VI underwent gamma-radi-
ation. All operations were done under sterile con-
ditions. The grafts were implanted into a
subcutaneous pouch. Contamination was not carried
out in all groups. The groups undergoing contami-
nation received 0.2 ml 2 £ 107 S. aureus ATCC 25923
(Max von Pettenkofer-Institut fu¨r Hygiene und Med-
izinische Mikrobiologie, Mu¨nchen, Großhadern,
Germany) directly onto the graft at the end of the
procedure prior to closing the skin. This dosage was
used since it caused reproducibly infection of the
prosthetic material.10 There were six animals in each
group.
Group I. Control group, gelatine-sealed dacron graft
(Uni-GraftwDV); no contamination.
Group II. Control group gelatine-sealed dacron graft
(Uni-GraftwDV), local contamination with S. aureus
(1 £ 107).
Group III. Silver/collagen coated dacron graft
(Intergardw), local contamination with S. aureus
(1 £ 107).
Group IV. Silver/gelatine-sealed dacron graft not
commercially available, local contamination with S.
aureus (1 £ 107).
Group V. Rifampin-impregnated gelatine-sealed
dacron graft (Uni-GraftwDV), local contamination
with S. aureus (1 £ 107). The graft material was in
analogy to the clinical procedure bathed in a concen-
tration of 60 mg/ml Rifampin (Rifaw parenteral
600 mg, Gru¨nenthal GmbH, Stolberg, Germany) for
15 min at 37 8C.
Group VI. Triclosan/collagen-coated dacron graft
(Intergardw Intervascular), local contamination with S.
aureus (1 £ 107). Triclosan (Irgasanw) was bonded
directly to the polyester of the graft by means of van
der Waal’sche forces as has been reported.11
Surgical technique
All mice were anaesthetised with Isofluran (Forenew)
employing the Isofluran Vaporiser 19,3 (Dra¨ger AG,
Lu¨beck) in combination with a oxygen laughing gas
mixture. The animals were fixed on their back, the
abdominal wall was shaved and disinfected with an
alcohol 75%. Under sterile conditions the abdominal
midline incision was carried out followed by the
preparation of a subcutaneous pouch to the left. The
0.8 £ 1 cm graft was implanted into this pouch. In
groups II–VI local contamination of the graft with S.
aureus was then carried out. The incision was closed
with subcutaneous and skin sutures (Ethicon, Ethi-
bondw 5/0) followed by a spray dressing.
Postoperative course
The animals and the wounds were checked daily for
progress in healing and signs of wound infection. Six
animals were kept as a group in Macrolonw Nr.2 cages
and received a standard diet as well as water ad
libitum. During the entire study the animals were kept
at the Institute of Surgical Research (LMU Munich)
under veterinary supervision.
Euthanasia and sampling
On postoperative day 14 animals were euthanised
with an isofluran overdose. This observation has been
chosen based on previous studies examining antimi-
crobial properties of vascular graft material.12 The
explantation of the grafts as well as the perigraft tissue
was carried out under sterile conditions; the samples
were transferred to sterile vessels and examined.
Rifampin and Silver Coating of Dacron Vascular Grafts 551
Eur J Vasc Endovasc Surg Vol 26, November 2003
Microbiological examination
Swabs, grafts and perigraft tissue were examined. The
material was stored under sterile conditions. In
positive samples the microorganisms were identified
with standard techniques used in clinical practice in
the Institute of Microbiology of the Ludwig-Maximi-
lians-University, Klinikum Großhadern. In order to
improve the yield of the samples the graft tissue and
perigraft tissue was trypsinised. One hundred micro-
litre of the bacterial suspension was applied to blood
agar. In positive cultures the microorganisms were
identified. If Staphylococci were found a combined
latex hemagglutinine test for the proof of clamping
factor and protein A as well as other specific antigens
of S. aureus (Slidex Staph-Kit, Fa. Bio Me´rieux) allowed
the differentiation between S. aureus and coagulase-
negative staphylococci. In the case of uncertain
reactions further diagnostics were performed using
biochemical identification with a commercial identifi-
cation system (API ID32 Staph, Fa. Bio Me´rieux). The
degree of bacterial contamination of the perigraft
tissue was semiquantitatively assessed two double-
blinded researchers and described as low ‘ þ ’,
moderate ‘þþ ’ and high ‘þþþ ’.
Histopathological examination
Material from the graft and perigraft tissue underwent
histopathological examination and semiquantitative
evaluation concerning the degree of inflammation. A
grading from 1 to 3 was carried out: low ‘1’, moderate
‘2’ and high ‘3’.
Statistics
The aim of the evaluation was to identify infection. It
was defined via the criteria ’microbiological contami-
nation‘ and/or ’histopathological signs‘. We are deal-
ing with a dichotome question. The probability of
error was calculated with the Fisher’s exact test
(probability of error #5%).
Results
Group I (control), n6
In all six animals there was no histological sign of
infection. In one animal there was erosion of the skin
with a migration of the graft material through the
incision. Here 103 S. epidermidis were found.
Group I showed 0 from six infections (see Table 1).
Group II (control, contamination), n6
Five out of six animals showed severe signs of
infection on histologic and microbiologic examination.
In all five cases S. aureus was recovered at numbers of
103–105. Infection with formation of a fistula led to the
loss of the graft material in the sixth animal on
postoperative day 7. Thus, further evaluation was not
possible. Nonetheless, macroscopically there were
clear signs of infection.
Group II was evaluated to have 6 out of 6 infections
(see Table 2).
Group III (Intergardw-Silver, contamination) n6
In group III extensive infection was found in all
animals. Macroscopically, histologically and micro-
biologically all grafts were found to be infected. In all
animals the inoculated S. aureus was recovered in at
numbers of 104–105. One graft sample could for
technical reason not be evaluated. The degree of
inflammation of the graft material was severe (4 £ 2,
1 £ 3).
In group III 6 out of 6 infections were found (see
Table 3).
Group IV (silver test graft, contamination), n6
Extensive infection was present in all cases. The
inoculated S. aureus was recovered from all grafts.
Histologically all grafts were considered to be infected
yet infection was not as extensive when compared to
the Intergardw-Silver graft. The degree of inflam-
mation of the graft material was low (4 £ 1, 1 £ 2).
In group IV there were 6 out of 6 infections (see
Table 4).
Group V (Rifampin, contamination), n6
In group V there was infection only in one animal. 105
S. aureus was recovered from the graft.
Group V was evaluated to have 1 out of 6 infections
(see Table 5).
Group VI (Triclosan, contamination), n6
In group VI there were four cases of infection on
histological and microbiological evaluation. One peri-
graft tissue sample could for technical reasons not be
evaluated. The degree of inflammation of the graft
material was low (3 £ 1, 3 £ 2).
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In group VI there were 4 out of 6 infections (see
Table 6). Data is summarised in Table 7.
Discussion
Several studies compare the efficiency of various
substances bounded to dacron graft material in
preventing graft infection.11,13 – 15 The aim of our
study was to compare the recently introduced agents
with well investigated substance Rifampin in an
experimental subcutaneous infection model.
In this regard, the formally tuberculostatic drug
Rifampin has been shown to be an effective antimi-
crobial agent against typical bacteria responsible for
vascular graft infections in vitro.15,16 Due to its very
poor water solubility high concentrations of the
substance can be reached in the vicinity of the graft
over a long period of time.17,18 Previously, Rifampin
was tested with commercially available gelatine-
coated dacron grafts demonstrating an adequate
affinity between gel-sealed dacron grafts and Rifam-
pin.15,16,19 – 21 Those properties of Rifampin appear to
be responsible for the positive results of this agent in
preventing graft infection in vivo in clinical and
experimental studies.22 – 26 Conversely, Koshiko et al.27
points out that Rifampin failed to demonstrate
effective antimicrobial effects against certain S. aureus
strains, i.e. MRSA. This has to be taken into account
when interpreting studies using Rifampin as an
antimicrobial agent. In our study, we focussed on S.
aureus (ATCC 25923), a common bacteria involved in
graft infections. Our results demonstrate an effective
bacterial killing in Rifampin coated vascular graft
material. It should be noted that two prospective
clinical trials improved local wound healing, however,
failed to significantly decrease the local rate of graft
infections.25,28
Therefore, additional agents have to be tested in
experimental studies. In 1996 Manouguian9 for the
first time reported the use of an antimicrobial
substance Triclosan binding directly via van der
Waal’sche forces to polyester graft material.11 In this
manuscript, the authors only reported the successful
clinical use of this Triclosan-coated vascular graft. In a
pig animal experimental model our group10 could
demonstrate the efficacy of such Triclosan-coated
vascular grafts following femoral vessel replacement.
Following local contamination all grafts of the unpro-
tected control group were infected (8 of 8) while none
of the Triclosan/collagen-coated dacron grafts devel-
oped infection (0 of 7). In vitro it could be shown that
Triclosan stays on the graft for more than 4 weeks.11 In
the present infection model with implantation of
Table 1. Group I (control), microbiological and histological results: silver-free gelatine-coated dacron graft (Uni-GraftwDV).
Animal no. Microbiological evaluation Histolog. Evaluation
Graft Perigraft tissue Graft Macroscop. Comment
1 – – 1 –
2 – – 1 –
3 – – 1 –
4 – – 1 –
5 – – 1 –
6 103 S. epidermis – 1 – Erosion
Infections 0/6
–: No infection; 1, 2 and 3: Degree of inflammation after histological evaluation (semiquantitative: 1: low, 2: middle, 3: high).
Table 2. Group II, microbiological und histological results: silver-free gelatine-coated dacron graft (Uni-GraftwDV) and local
contamination with 0.2 ml 2 3 107 Staphylococcus aureus ATCC 29213.
Animal no. Microbiological evaluation Histolog. Evaluation
Graft Perigraft tissue Graft Macroscop. Comment
1 .1000 S. aureus þþþ 3 þ
2 .1000 S. aureus þþþ 3 þ
3 / / / þ Graft lost via fistula
4 104 S. aureus þþ 2 þ
5 105 S. aureus þþ 2 þ
6 105 S. aureus þþ 2 þ
Infections 6/6
þ : Macroscopical sign of infection; þ , þþ and þþþ : Positive contamination after microbiological examination of the perigraft
tissue(semiquantitative). 1, 2 and 3: Degree of inflammation after histological evaluation (semiquantitative: 1: low, 2: middle, 3: high).
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alloplastic graft material subcutaneously in mice
Triclosan also decreased the infection rate. This
therapeutic effect, however, was not significant. In
contrast, previously our group demonstrate efficacy of
Triclosan in preventing graft infection in an arterial
interposition model.10 Thus, decreasing the bacterial
load in the present study might better demonstrate the
antimicrobial potential of Triclosan also in the subcu-
taneous area. It should be pointed out, that our model
clearly discriminates between Rifampin coated and
non-treated prosthetic material. Rifampin-bonded gel-
sealed vascular graft almost completely prevented
infection of graft material.
In addition, the hemodynamic effect in the pig
model in contrast to the subcutaneous model might
contribute to the observed difference. This notion
remains to be determined.
At the end of the 1980s silver-coated graft material
was examined. Silver is a broad-spectrum bacterio-
static agent. Silver binds to the microbial DNA and
prevents bacterial replication.29 – 31 Medical instru-
ments such as central venous lines, urinary catheters,
peritoneal catheters, vascular grafts, cardiac valves,
suture material and bone implants have been coated
with silver. Already at the end of the 1980s examin-
ation of PTFE grafts and silver derivatives was carried
out. Coating PTFE grafts with silver derivatives was
carried out in order to bind antibiotics. The bonded
antibiotics were liberated in two phases. Half of the
substance was given off immediately and in the
second phase the remaining substance was slowly
given off over a longer period to the surrounding
tissue.32 Shah et al.33 carried out their trials in dogs.
Following the challenge with S. aureus and E. coli after
the implantation of a PTFE graft treated with
Norfloxacin (control) and silver-norfloxacin (AGNF)
they found no infection in seven animals (0 of 7) in
compared to 6 of 7 infected grafts in the control group.
Kinney et al.34 also reported after using PTFE grafts
with and without silver coating about positive effects
of silver in combination with ciprofloxacin bonded to
vascular grafts. In an in vivo trial in dogs he only
found a moderate reduction of the rate of vascular
grafts infection following the challenge with S. aureus
and E. coli.
Benvenisty35 as well could demonstrate an effect of
silver-coated vascular grafts in an animal model in the
dog. However, he could only detect a reduction in the
Table 3. Group III, microbiological and histological results: Silver Intergardw graft and local contamination with 0.2 ml 2 3 107
Staphylococcus aureus ATCC 29213.
Animal no. Microbiological evaluation Histolog. Evaluation
Graft Perigraft tissue Graft Macroscop. Comment
1 104 S. aureus þþ 2 þ Erosion
2 105 S. aureus þþþ 2 þ Erosion
3 104–105 S. aureus þþ 3 þ Abscess
4 104 S. aureus þþ 2 þ Abscess
5 105 S. aureus þþ 2 þ abscess
6 105 S. aureus þþ – þ
Infections 6/6
–: No infection; þ : Macroscopical sign of infection; þ , þþ and þþþ : Positive contamination after microbiological examination of the
perigraft tissue (semiquantitative); 1, 2 and 3: Degree of inflammation after histological evaluation (semiquantitative: 1:low, 2: middle, 3:
high).
Table 4. Group IV, microbiological and histological results: Not commercially available silver/gelatine-coated dacron graft and
contamination with 0.2 ml 2 3 107 Staphylococcus aureus ATCC 29213.
Animal no. Microbiological evaluation Histolog. Evaluation
Graft Perigraft tissue Graft Macroscop. Comment
1 103 S. aureus þþ 2 þ Abscess
2 103 S. aureus – 1 þ
3 103 S. aureus – 1 þ
4 103 S. aureus þþ 1 þ
5 103 S. aureus þþ 1 þ
6 103 S. aureus – 1 þ Abscess
Infections 6/6
–: No infection; þ : Macroscopical sign of infection; þ , þþ and þþþ : Positive contamination after microbiological examination of the
perigraft tissue (semiquantitative); 1, 2 and 3: Degree of inflammation after histological evaluation (semiquantitative: 1:low, 2: middle, 3:
high).
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concentration of the inoculated S. aureus on grafts at
the end of the trial. Based on those results recent
studies have been initiated determining the effect of
silver in protecting graft material infections. Only for
silver coating of cardiac valve material and intrave-
nous lines protective effects have been reported. In this
respect, Illingworth29 could show a clear reduction in
the number of infections following subdermal implan-
tation of silver-coated polyester cardiac valves in a pig
infection model. Collin36 found a significant reduction
of bacterial contamination of central venous lines.
Only two of 98 silver-coated central venous catheters
showed signs of infection in comparison to 25 out of
139 infected not silver-protected ones.
Although no standardised data exists concerning
the antimicrobial properties of silver coated vascular
graft material, a commercially available silver coated
dacron graft for the treatment of graft infection is
used clinically. In the present paper a direct
comparison of the silver-coated Intergardw-Silver
vascular graft as well as the not commercially
available silver-protected vascular graft with anti-
microbially impregnated gel-sealed dacron grafts
(Rifampin) has been carried out. In contrast to
Rifampin, silver coated to vascular graft material
had no effect on the infection rate in the present
study. Support for these findings comes from
studies of Goe¨au-Brissonnie`re et al.,37 who demon-
strated no effect of silver in preventing graft
infection in a dog infection model. In contrast,
Rifampin completely prevented graft infection in the
experiments of Goe¨au-Brissonnie`re et al.37
In summary, the present studies compared the
antimicrobial properties of two new prophylactic
agents with the established Rifampin in a subcu-
taneous infection model. The results indicate that
silver coating of prosthetic material failed to prevent
graft infection. In contrast, Triclosan coating decreased
the infection rate of prosthetic material. This effect,
however, was not significant. Those findings together
with our previous positive results in an arterial
reposition pig model suggest that Triclosan exhibits
an antimicrobial potential. Rifampin, however,
showed the best antimicrobial property. Therefore,
silver coated vascular material should not be rec-
ommended in case of vascular graft infection.
Table 5. Group V, microbiological and histological results: gel-sealed dacron graft (Uni-GraftwDV) with Rifampin-impregnation and
contamination with 0.2 ml 2 3 107 Staphylococcus aureus ATCC 29213.
Animal no. Microbiological evaluation Histolog. Evaluation
Graft Perigraft tissue Graft Macroscop. Comment
1 – – 1 –
2 – – 1 –
3 – – 1–2 –
4 – – 0–1 –
5 105 S. aureus þ 2 þ
6 – – 1–2 –
Infections 1/6
–: No infection; þ : Macroscopical sign of infection; þ , þþ and þþþ : Positive contamination after microbiological examination of the
perigraft tissue (semiquantitative); 1, 2 and 3: Degree of inflammation after histological evaluation (semiquantitative: 1:low, 2: middle, 3:
high).
Table 6. Group VI, microbiological and histological results: Triclosan (10 g/l)/collagen-coated dacron graft and contamination with 0.2 ml
2 3 107 Staphylococcus aureus ATCC 29213.
Animal no. Microbiological evaluation Histolog. Evaluation
Graft Perigraft tissue Graft Macroscop. Comment
1 105 S. aureus þþ 2–3 þ Arrosion
2 103 S. aureus þþ 2–3 þ
3 103 S. aureus – 1–2 þ
4 105 S. aureus þþ 2 þ Abscess
5 – – 1–2 þ
6 – – 0–1 þ
Infections 4/6
–: No infection; þ : Macroscopical sign of infection; þ , þþ and þþþ : Positive contamination after microbiological examination of the
perigraft tissue (semiquantitative); 1, 2 and 3: Degree of inflammation after histological evaluation (semiquantitative: 1:low, 2: middle, 3:
high).
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